Market Research Logo

Acute Heart Failure - Pipeline Review, H1 2015

Acute Heart Failure - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Acute Heart Failure - Pipeline Review, H1 2015’, provides an overview of the Acute Heart Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Heart Failure and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Acute Heart Failure Overview
Therapeutics Development
Pipeline Products for Acute Heart Failure - Overview
Pipeline Products for Acute Heart Failure - Comparative Analysis
Acute Heart Failure - Therapeutics under Development by Companies
Acute Heart Failure - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Heart Failure - Products under Development by Companies
Acute Heart Failure - Companies Involved in Therapeutics Development
Amgen Inc.
Anexon, Inc.
Angion Biomedica Corp.
Bayer AG
Lee's Pharmaceutical Holdings Limited
Novartis AG
Nyken BV
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Trevena, Inc.
Acute Heart Failure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ANG-4011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANX-042 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BR-5489 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cenderitide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
istaroxime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYK-1112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omecamtiv mecarbil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-4232 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PB-1046 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
serelaxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRV-027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRV-120023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ularitide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Heart Failure - Recent Pipeline Updates
Acute Heart Failure - Dormant Projects
Acute Heart Failure - Discontinued Products
Acute Heart Failure - Product Development Milestones
Featured News & Press Releases
Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide
Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027
May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting
May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure
Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
Mar 25, 2014: FDA Staff Says Novartis’ Serelaxin Shouldn’t Be Approved
Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion
Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Heart Failure, H1 2015
Number of Products under Development for Acute Heart Failure - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Acute Heart Failure - Pipeline by Amgen Inc., H1 2015
Acute Heart Failure - Pipeline by Anexon, Inc., H1 2015
Acute Heart Failure - Pipeline by Angion Biomedica Corp., H1 2015
Acute Heart Failure - Pipeline by Bayer AG, H1 2015
Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015
Acute Heart Failure - Pipeline by Novartis AG, H1 2015
Acute Heart Failure - Pipeline by Nyken BV, H1 2015
Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015
Acute Heart Failure - Pipeline by Trevena, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Acute Heart Failure Therapeutics - Recent Pipeline Updates, H1 2015
Acute Heart Failure - Dormant Projects, H1 2015
Acute Heart Failure - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Acute Heart Failure, H1 2015
Number of Products under Development for Acute Heart Failure - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report